Kala Pharmaceuticals, Inc. (0JQ2.L)
USD 3.17
(4.24%)
USD 3.17
(4.24%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -303 Thousand USD | -122.75% |
| 2022 | 1.33 Million USD | -81.35% |
| 2021 | 7.14 Million USD | 123.99% |
| 2020 | 3.18 Million USD | -21.57% |
| 2019 | 4.06 Million USD | 525.76% |
| 2018 | -955 Thousand USD | -48.52% |
| 2017 | -643 Thousand USD | -116.5% |
| 2016 | -297 Thousand USD | -760.0% |
| 2015 | 45 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -66 Thousand USD | 0.0% |
| 2024 Q2 | -61 Thousand USD | 7.58% |
| 2023 Q1 | -87 Thousand USD | 93.47% |
| 2023 Q3 | -157 Thousand USD | -103.9% |
| 2023 Q2 | -77 Thousand USD | 11.49% |
| 2023 FY | -303 Thousand USD | -122.75% |
| 2023 Q4 | - USD | 100.0% |
| 2022 FY | 1.33 Million USD | -81.35% |
| 2022 Q4 | -1.33 Million USD | -425.67% |
| 2022 Q3 | 409 Thousand USD | 25.46% |
| 2022 Q2 | 326 Thousand USD | -45.39% |
| 2022 Q1 | 597 Thousand USD | 36.3% |
| 2021 Q1 | 2.51 Million USD | 185.67% |
| 2021 Q3 | 2.15 Million USD | 6.09% |
| 2021 Q4 | 438 Thousand USD | -79.71% |
| 2021 Q2 | 2.03 Million USD | -18.96% |
| 2021 FY | 7.14 Million USD | 123.99% |
| 2020 Q2 | 74 Thousand USD | -89.68% |
| 2020 Q4 | 879 Thousand USD | -42.13% |
| 2020 Q1 | 717 Thousand USD | 65.59% |
| 2020 FY | 3.18 Million USD | -21.57% |
| 2020 Q3 | 1.51 Million USD | 1952.7% |
| 2019 Q1 | 1.14 Million USD | 0.0% |
| 2019 FY | 4.06 Million USD | 525.76% |
| 2019 Q4 | 433 Thousand USD | -44.7% |
| 2019 Q3 | 783 Thousand USD | -54.08% |
| 2019 Q2 | 1.7 Million USD | 48.91% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | -955 Thousand USD | -48.52% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | -643 Thousand USD | -116.5% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 FY | -297 Thousand USD | -760.0% |
| 2015 FY | 45 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 101.75% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 200.331% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 103.017% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 100.006% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 100.028% |
| Homology Medicines, Inc. | -7.22 Million USD | 95.809% |
| Imunon, Inc. | -720 Thousand USD | 57.917% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 96.833% |
| uniQure N.V. | 2.21 Million USD | 113.679% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 99.644% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 100.084% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 3.195% |
| bluebird bio, Inc. | -4.03 Million USD | 92.481% |
| Blueprint Medicines Corporation | 236.58 Million USD | 100.128% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 102.048% |
| Adicet Bio, Inc. | -6.09 Million USD | 95.031% |
| Dynavax Technologies Corporation | 182.11 Million USD | 100.166% |
| Geron Corporation | -123.5 Million USD | 99.755% |
| Illumina, Inc. | 2.74 Billion USD | 100.011% |
| Myriad Genetics, Inc. | 476.4 Million USD | 100.064% |
| Verastem, Inc. | -62 Thousand USD | -388.71% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.004% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.002% |
| Biogen Inc. | 7.3 Billion USD | 100.004% |
| Nektar Therapeutics | 53.47 Million USD | 100.567% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -3.767% |
| Perrigo Company plc | 1.68 Billion USD | 100.018% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 98.462% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.016% |
| Editas Medicine, Inc. | -99.52 Million USD | 99.696% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 100.415% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 100.014% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 100.058% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.001% |
| Waters Corporation | 1.76 Billion USD | 100.017% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 99.028% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 100.016% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 99.331% |
| Evolus, Inc. | 140.52 Million USD | 100.216% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.003% |
| FibroGen, Inc. | 128.9 Million USD | 100.235% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 100.009% |
| OPKO Health, Inc. | 318.12 Million USD | 100.095% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 100.02% |
| Exelixis, Inc. | 1.75 Billion USD | 100.017% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 99.924% |
| Zoetis Inc. | 5.83 Billion USD | 100.005% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 100.124% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 100.039% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 100.064% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 100.048% |
| Insmed Incorporated | 239.63 Million USD | 100.126% |
| TG Therapeutics, Inc. | 219.1 Million USD | 100.138% |
| Incyte Corporation | 3.44 Billion USD | 100.009% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 100.088% |